A randomised trial comparing combination chemotherapy using mitomycin C, mitozantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer
- 1 August 1991
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 64 (2), 406-410
- https://doi.org/10.1038/bjc.1991.318
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer.Journal of Clinical Oncology, 1988
- Improving the Quality of Life during Chemotherapy for Advanced Breast CancerNew England Journal of Medicine, 1987
- A randomized study of intensive versus moderate chemotherapy programs in metastatic breast cancerCancer, 1987
- A phase I-II study of intensive-dose adriamycin for advanced breast cancer.Journal of Clinical Oncology, 1987
- High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer.Journal of Clinical Oncology, 1986
- Comparison of CAF versus CMFP in metastatic breast cancer: analysis of prognostic factors.Journal of Clinical Oncology, 1985
- Mitomycin C, melphalan and methotrexate combination chemotherapy for palliation of disseminated breast cancerCancer Chemotherapy and Pharmacology, 1984
- FAILURE OF CHEMOTHERAPY TO PROLONG SURVIVAL IN A GROUP OF PATIENTS WITH METASTATIC BREAST CANCERThe Lancet, 1980
- ASSESSMENT OF BIOCHEMICAL TESTS TO SCREEN FOR METASTASES IN PATIENTS WITH BREAST CANCER*1The Lancet, 1980
- Chemotherapy of disseminated breast cancer:Current status and prospectsCancer, 1977